NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and Wilex AG today announced an agreement for Nuclea to purchase Wilex Inc., a wholly owned subsidiary of Wilex AG.

Under the terms of the deal, Nuclea is purchasing all the shares of Wilex Inc. In addition to assuming all of the company's assets, Nuclea assumes responsibility for repayment of a $2.5 million loan between Wilex Inc. and Wilex AG.

Wilex AG is also eligible for single-digit royalties on net sales of Wilex Inc.'s HER2/neu and carbonic anhydrase IX, or CAIX, assays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
27
Sponsored by
Roche

This webinar will present data from the FLAURA trial and show the clinical utility of liquid biopsy in identifying non-small-cell lung cancer (NSCLC) patients who may benefit from targeted TKI therapies.